NEW YORK (GenomeWeb News) â€" In a pair of papers appearing online today in the Lancet and Lancet Oncology, members of the Breast Cancer Intergroup of North America reported that some post-menopausal, estrogen receptor positive breast cancer patients benefit from the addition of chemotherapy to standard tamoxifen treatment.

And, the researchers found, the addition of chemotherapy was most beneficial for individuals scoring high on Genomic Health's Oncotype DX test, suggesting the recurrence assay may be helpful for guiding such treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.